Clinical Trial Update: Efficacy and Safety of Topical Cyclosporine 0.05% and Lifitgrast on the Ocular Surface Symptom After Photorefractive Keratectomy in Feiz Hospital, Isfahan, 2024 [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the safety and efficacy of topical cyclosporine 0.05% and lifitegrast for ocular surface symptoms after photorefractive keratectomy, cu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ocular Surface Disease

Drugs mentioned

• Restasis (Cyclosporine A)
• Xiidra (Lifitegrast)

Snippet

Sponsor: Mohsen Pourazizi | Conditions: Ocular Surface Symptom, Ocular Surface Disease | Phase 1 | Status: NOT_YET_RECRUITING